文献速递血栓与止血

难治性免疫性血小板减少症的新型治疗药物与未来方向

Novel therapeutics and future directions for refractory immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2023-01-01

免疫性血小板减少症(ITP)约每2万人中影响1人,现有标准治疗下仍有部分患者无法充分控制而成为难治性ITP。本文综述了正处于2期或3期研究的新型药物,包括efgartigimod、rilzabrutinib、sutimlimab、iptacopan及抗CD38单抗等,并讨论了难治性ITP药物开发的未来方向。

要点

  • 难治性ITP患者并不少见,现有标准治疗下仍存在未满足的临床需求。
  • 多种针对新靶点的新型药物正在2期或3期研究中,主要招募经重度预处理或难治性患者。
  • 未来药物开发需关注创新试验设计、健康相关生活质量终点及毒性获益平衡。

核心结论

  • 难治性ITP患者并不少见,仍存在对新治疗药物和药物开发的持续需求。
  • 多种利用新靶点或新机制的新型药物正在2期或3期研究中,主要招募经重度预处理或难治性患者。
  • 未来难治性ITP药物开发方向包括创新临床试验设计、将健康相关生活质量作为不可或缺的临床试验终点,以及在有出血性疾病中平衡药物潜在毒性与潜在获益。

研究设计与样本

  • 本文为综述,汇总目前正在经重度预处理或难治性ITP患者中开展2期或3期研究的新型治疗药物的现有数据。

主要发现

  • 正在临床开发的新型药物包括新生儿Fc受体拮抗剂efgartigimod、布鲁顿酪氨酸激酶抑制剂rilzabrutinib、补体抑制剂sutimlimab和iptacopan以及抗CD38单克隆抗体daratumumab和mezagitamab等。
  • 这些药物的治疗靶点或ITP病理生理环节目前未被现有获批药物(血小板生成素受体激动剂和fostamatinib)所靶向。
  • 相关试验主要招募经重度预处理的患者和难治性患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting approximately 1 in 20 000 people. While most patients with ITP are successfully managed with the current set of standard and approved therapeutics, patients who cannot be adequately managed with these therapies, considered to have refractory ITP, are not uncommon. Therefore, there remains an ongoing need for novel therapeutics and drug development in ITP. Several agents exploiting novel targets and mechanisms in ITP are presently under clinical development, with trials primarily recruiting heavily pretreated patients and those with otherwise refractory disease. Such agents include the neonatal Fc receptor antagonist efgartigimod, the Bruton tyrosine kinase inhibitor rilzabrutinib, the complement inhibitors sutimlimab and iptacopan and anti-CD38 monoclonal antibodies such as daratumumab and mezagitamab, among others. Each of these agents exploits therapeutic targets or other aspects of ITP pathophysiology currently not targeted by the existing approved agents (thrombopoietin receptor agonists and fostamatinib). This manuscript offers an in-depth review of the current available data for novel therapeutics in ITP presently undergoing phase 2 or 3 studies in patients with heavily pretreated or refractory ITP. It additionally highlights the future directions for drug development in refractory ITP, including discussion of innovative clinical trial designs, health-related quality of life as an indispensable clinical trial end-point and balancing potential toxicities of drugs with their potential benefits in a bleeding disorder in which few patients suffer life-threatening bleeding.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H, Neufeld EJ. Novel therapeutics and future directions for refractory immune thrombocytopenia. Br J Haematol. 2023. PMID: 37735554. doi:10.1111/bjh.19078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。